Page 16 - Solid Biosciences News Today

Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights What happened Shares of Solid Biosciences (NASDAQ:SLDB) had crashed 31% lower as of 11:15 a.m. EDT on Tuesday. The company announced interim results from a phase 1/2 study of ...

Shares of Solid Biosciences  ( SLDB) - Get Report dropped Tuesday after the developer of a Duchenne muscular-dystrophy treatment reported that a patient had an adverse event in an trial of its gene-therapy candidate.  The Cambridge, Mass., company said that six patients in its ongoing clinical study showed promising results.  A seventh patient "was safely dosed, with transient and manageable adverse events, none of which were serious," it said in a statement "The totality of data collected,...

Order Reprints Text size Many analysts lowered their price targets for Sarepta after the news, though only four downgraded the stock. Dreamstime Until Thursday, Sarepta Therapeutics led the race to prove that gene therapy could cure Duchenne muscular dystrophy, a genetic disorder that progressively weakens the muscles of children. Late in the day, however, the company announced that a controlled trial of its gene therapy failed to improve the average muscle stre...

Engaged Capital initiated a 9.96% position in the health-care, administrative-services tech firm, equal to 8,553,155 Evolent Health shares. That position has remained unchanged, as noted by Engaged Capital’s latest disclosure. What has changed is that Engaged and Evolent entered into a cooperation agreement as of Dec. 21. Per the agreement, Evolent will increase the size of its board by one to accommodate the appointment of an Engaged representative to serve until at least next year’s annua...